Company Overview: ClinActiv is a newly established China-to-global dermatology consumer health platform, leveraging collagen-based late-stage assets, global M&A and biomaterial R&D to build a global footprint from day one. With the founder’s proven track record and strategic resources, ClinActiv aims to grow into a Galderma-scale dermatology leader, powered by innovation and cash-generating acquisitions. Assets and growth drivers China Collagen Pipeline: Bovine, recombinant, and triple-helix collagen assets, several already at NDA filing or near-approval stage, with key applications in skin care, injectable aesthetics and wound repair. Scarce animal-derived collagen capacity as initial edge: ClinActiv controls ~20kg/year; by comparison, leading competitor sustains ~RMB 300m revenue with only 5kg, highlighting ClinActiv’s rare and highly differentiated entry point. North America Expansion via clear M&A target: Acquisition in progress of a long-term partner with established brands, CDMO infrastructure and commercial coverage, providing immediate global footprint and cash flow. R&D Ecosystem: Partnering with leading academic institutions to drive biomaterial innovation and sustain next-generation skincare pipelines. Founder track record Entrepreneurship: A successful serial entrepreneur with a history of building and scaling ventures across consumer health and life sciences. Strategic Background: Largest shareholder of Waldencast (NASDAQ: WALD), which owns Obagi, one of the most iconic global skincare brands, while also retaining direct ownership of Obagi China. Brings deep expertise across skincare, consumer healthcare management, global M&A, and international operations, backed by a strong global network. Investor backing Incubated by Hongshan (ex-Sequoia China) and supported by Hillhouse, demonstrating strong confidence in ClinActiv’s model.